ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0568

Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0693

Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0445

Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study

(0423–0459) RA – Treatments Poster I

9:00AM-11:00AM: Abstract Number: 0656

Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0477

Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC

(0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0645

Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0472

Contraception Choices in Individuals with Inflammatory Arthritis and Lupus-like Disease Differ Based on Diagnosis and Teratogen Use

(0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0336

Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0064

Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0155

Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0177

Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities

(0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

9:00AM-11:00AM: Abstract Number: 0412

COVID Antibody Response to Third Dose Anti-SARS-COV2 mRNA Vaccine in Patients with Seropositive Rheumatoid Arthritis on Immunosuppressive Therapy

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0612

COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0144

COVID-19 Infection in People with Immune Mediated Inflammatory Diseases Who Received SARSCo-V2 Vaccines

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0211

COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study

(0196–0228) Infection-related Rheumatic Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].